Supply of products by Merck Sharp & Dohme (Australia) Pty Limited

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that these products are safe, of acceptable quality, and properly represented. This Act was introduced to address the need for a cohesive and effective regulatory framework governing the approval, manufacture, and distribution of therapeutic goods, including medicines, medical devices, and blood products. The Act is administered by the Therapeutic Goods Administration, an agency of the Australian Government's Department of Health. The policy objective behind the Act is to protect public health by ensuring that therapeutic goods available in Australia meet the necessary safety, quality, and efficacy standards. In the context of the Therapeutic Goods Act 1989, the Delegate of the Secretary to the Department of Health and Ageing has exercised their authority to grant specific consents for the supply of certain therapeutic goods that may not fully comply with particular labelling requirements. This consent, as evidenced in the gazette, allows Merck Sharp & Dohme (Australia) Pty Limited to supply certain batches of medicines where the labels do not include the name and address of the current sponsor, subject to specific conditions to ensure that consumers can still be adequately informed and that there is a mechanism for redirecting any inquiries to the current sponsor. This measure demonstrates the flexibility within the legislative framework to address unique situations while maintaining the overarching goal of protecting public health.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring that such goods meet quality, safety, and efficacy standards. Under sections 14, 14A, and 15 of the Act, the Secretary to the Department of Health and Ageing, or their delegate, can provide consent for the supply of therapeutic goods that do not fully comply with certain regulatory requirements, subject to specified conditions. In this case, the delegate has authorised Merck Sharp & Dohme (Australia) Pty Limited to supply specific batches of medicines that do not meet the labelling requirement of including the current sponsor's name and address. This consent is limited to the particular batches listed in the attachment and is contingent upon compliance with other labelling regulations, as well as the inclusion of the previous sponsor's details and the redirection of any related correspondence to the current sponsor's address. This legislative provision allows for flexibility in exceptional cases while maintaining overall regulatory oversight.

Key Provisions

The Therapeutic Goods Act 1989, as evidenced by the notice issued on 23 June 2013 by Mayada Kayali, Delegate of the Secretary, provides specific authorisation for Merck Sharp & Dohme (Australia) Pty Limited to supply certain batches of medicines that do not fully comply with the label requirements outlined in the Therapeutic Goods Order No. 69 (section 14). The consent granted is limited to specific batches of Tinaderm tolnaftate, Tinaderm Powder, Prantal Powder, and Solarcaine Spray (section 14A). This authorisation is given under the condition that these medicines must adhere to all other labelling requirements and must include the name and address of the previous sponsor, Schering-Plough Pty Ltd, on their labels (section 14(1)). The obligations imposed on Merck Sharp & Dohme (Australia) Pty Limited under this Act are stringent. They must ensure that the medicines supplied meet all labelling requirements except for the specific condition mentioned in the consent notice. This means that while the current sponsor's details may not be included, the previous sponsor's details must be prominently displayed. Furthermore, the company is required to re-direct any communications intended for Schering-Plough Pty Ltd to the current sponsor’s address to maintain continuity of customer support and regulatory compliance (section 15). Failure to comply with the conditions stipulated in the consent notice may result in severe consequences. Under the Therapeutic Goods Act 1989, breaches can lead to civil and criminal penalties. Civil penalties for non-compliance can include fines and corrective actions mandated by the Therapeutic Goods Administration (TGA). The Act does not specify a maximum penalty for these civil offences, but it is understood that they can be substantial and vary based on the severity and frequency of the breach. Additionally, if the breach is considered to be a criminal offence, the company or its representatives may face criminal prosecution, which could result in further penalties such as imprisonment, depending on the seriousness of the offence.